Filing Flows › Integrated Biopharma (INBP) › Gross margin
Integrated Biopharma (INBP) gross margin by quarter
Integrated Biopharma's gross margin was 8.0% in Q1 FY26 (first quarter fiscal 2026), -3.1 pts from Q3 FY25. Over the last 3 quarters it ranged from 8.0% (Q1 FY26) to 11.1% (Q3 FY25).
| Quarter | Gross margin | Q/Q | Y/Y |
|---|---|---|---|
| Q1 FY26 | 8.0% | -3.1 pts | — |
| Q3 FY25 | 11.1% | +1.8 pts | — |
| Q2 FY25 | 9.3% | — | — |
Q1 FY26 at a glance
Integrated Biopharma, Q1 FY26: revenue $12.7M (-7% year over year), operating margin 1.3%, net earnings $123K, operating cash flow $1.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is Integrated Biopharma's gross margin?
Integrated Biopharma's gross margin was 8.0% in Q1 FY26 (first quarter fiscal 2026), -3.1 pts from Q3 FY25.
How has Integrated Biopharma's gross margin changed?
Over the last 3 quarters it ranged from 8.0% (Q1 FY26) to 11.1% (Q3 FY25).